𝔖 Bobbio Scriptorium
✦   LIBER   ✦

“Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK”

✍ Scribed by Nick Bansback; Sue Ward; Jon Karnon

Book ID
106294826
Publisher
Springer
Year
2004
Tongue
French
Weight
152 KB
Volume
5
Category
Article
ISSN
1618-7598

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The pemetrexed/gemcitabine combination i
The pemetrexed/gemcitabine combination in pancreatic cancer
✍ Hedy Lee Kindler 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

Gemcitabine has modest antitumor activity in advanced pancreatic cancer. New agents are clearly needed. Pemetrexed (ALIMTA) is a novel antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed has shown in vitro activity agai

Combined gemcitabine and radioimmunother
Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer
✍ Thomas M. Cardillo; Rosalyn Blumenthal; Zhiliang Ying; David V. Gold 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 116 KB 👁 1 views

## Abstract MAb‐PAM4 is an anti‐MUC1 antibody that has been shown to be reactive with 85% of pancreatic adenocarcinomas with no reactivity with normal pancreas or other tissues. Initial clinical studies have shown excellent targeting with high tumor/nontumor ratios. Gemcitabine, an analog of deoxyc

On the development of gemcitabine-based
On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer
✍ Cornelius J. McGinn; Theodore S. Lawrence; Mark M. Zalupski 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

The use of chemotherapy with concurrent radiation therapy remains a standard treatment option for patients with unresectable or resected adenocarcinoma of the pancreas. This treatment strategy is based in large part on data from serial Gastrointestinal Tumor Study Group trials that have included 5-f